SELLAS Life Sciences Group (SLS) Common Equity: 2011-2023
Historic Common Equity for SELLAS Life Sciences Group (SLS) over the last 7 years, with Dec 2023 value amounting to -$8.0 million.
- SELLAS Life Sciences Group's Common Equity rose 515.26% to $15.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $15.9 million, marking a year-over-year increase of 515.26%. This contributed to the annual value of -$8.0 million for FY2023, which is 264.42% down from last year.
- Latest data reveals that SELLAS Life Sciences Group reported Common Equity of -$8.0 million as of FY2023, which was down 264.42% from $4.9 million recorded in FY2022.
- Over the past 5 years, SELLAS Life Sciences Group's Common Equity peaked at $28.0 million during FY2020, and registered a low of -$8.0 million during FY2023.
- In the last 3 years, SELLAS Life Sciences Group's Common Equity had a median value of $4.9 million in 2022 and averaged $5.7 million.
- Its Common Equity has fluctuated over the past 5 years, first surged by 358.90% in 2020, then plummeted by 264.42% in 2023.
- SELLAS Life Sciences Group's Common Equity (Yearly) stood at $6.1 million in 2019, then surged by 358.90% to $28.0 million in 2020, then fell by 27.23% to $20.3 million in 2021, then crashed by 76.16% to $4.9 million in 2022, then slumped by 264.42% to -$8.0 million in 2023.